









市场行情
/
股票
/
nasdaq-abvx
/

Abivax SA

ABVX

145.310USD

+6.960+5.03%

收盘 12/24, 13:00（美东）报价延迟15分钟

0.00总市值

--市盈率 TTM



Abivax SA

145.310

+6.960+5.03%

概览公司财务分析

概览

公司

财务

分析

关于 Abivax SA 公司

Abivax SA is a clinical stage biopharmaceutical company focusing on the discovery, development and commercialization of anti-viral compounds and therapeutic vaccines against severe and life threatening infectious diseases. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The Company's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Abivax SA简介



公司代码ABVX

公司名称Abivax SA

上市日期Jun 26, 2015

CEOde Garidel (Marc)

员工数量- -

证券类型Depository Receipt

年结日- -

公司地址7-11 Boulevard Haussmann

城市PARIS

上市交易所NASDAQ OMX - NASDAQ BASIC

国家France

邮编75009

电话33153830963

网址https://www.abivax.com/

公司代码ABVX

上市日期Jun 26, 2015

CEOde Garidel (Marc)

Abivax SA公司高管



名称

名称/职务

职务

持股

持股变动

Senior Vice President - Finance

Kevin Shan

Vice President, Global Head - Biometrics

Ms. Sophie Lacourrege

Vice President, HR Business Partner, Engagement and Culture

Nadege Briancon-eris

Senior Vice President, Global Head - Program Management

Jennifer Fine

Senior Vice President, Global Head - HEOR and RWE

Douglas Jacobstein

Senior Vice President, Global Head - Clinical Development

Mr. Jerome Denis, Ph.D.

Executive Vice President - Process Development & Manufacturing

Mary Mantock

Senior Vice President, Global Head - Regulatory Affairs

Mr. Patrick Malloy

Senior Vice President - Investor Relations

Mr. Didier Scherrer, Ph.D.

Chief Scientific Officer

名称

名称/职务

职务

持股

持股变动

Senior Vice President - Finance

Kevin Shan

Vice President, Global Head - Biometrics

Ms. Sophie Lacourrege

Vice President, HR Business Partner, Engagement and Culture

Nadege Briancon-eris

Senior Vice President, Global Head - Program Management

Jennifer Fine

Senior Vice President, Global Head - HEOR and RWE

Douglas Jacobstein

Senior Vice President, Global Head - Clinical Development

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月17日周一

持股股东

股东类型

持股股东

占比

TCG Crossover Management, LLC

9.67%

UBS Financial Services, Inc.

6.06%

Darwin Global Management Ltd

4.30%

Point72 Asset Management, L.P.

3.98%

Cormorant Asset Management, LP

2.65%

其他

73.34%

持股股东

占比

TCG Crossover Management, LLC

9.67%

UBS Financial Services, Inc.

6.06%

Darwin Global Management Ltd

4.30%

Point72 Asset Management, L.P.

3.98%

Cormorant Asset Management, LP

2.65%

其他

73.34%

股东类型

持股股东

占比

Hedge Fund

33.85%

Investment Advisor

22.65%

Investment Advisor/Hedge Fund

8.69%

Research Firm

2.98%

Venture Capital

2.18%

Private Equity

1.77%

Pension Fund

1.00%

其他

26.88%

机构持股



更新时间: 12月8日周一

报告期

机构数

持股数

持股占比

持股变动

2025Q4

216

53.64M

52.23%

+104.02K

2025Q3

210

53.54M

52.22%

+19.70M

2025Q2

30.74M

57.27%

-1.09M

2025Q1

31.82M

50.24%

-38.10K

2024Q4

29.91M

44.59%

+2.48M

2024Q3

27.43M

45.93%

-700.83K

2024Q2

33.52M

46.25%

-227.21K

2024Q1

28.78M

34.33%

+7.18M

2023Q4

27.04M

1.75%

+20.54M

2023Q3

5.40M

0.00%

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

TCG Crossover Management, LLC

6.06M

8.23%

Jun 30, 2025

Cormorant Asset Management, LP

2.13M

2.9%

Jun 30, 2025

Caligan Partners, LP

1.67M

2.28%

+405.28K

+31.93%

Jun 30, 2025

Fidelity Management & Research Company LLC

1.01M

1.38%

+75.30K

+8.03%

Aug 31, 2025

Adar1 Capital Management LLC

3.07M

4.17%

+861.32K

+38.97%

Jun 30, 2025

Octagon Capital Advisors LP

1.27M

1.72%

+37.00K

+3.01%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

Simplify Health Care ETF

2.86%

Harbor Health Care ETF

0.7%

Fidelity Nasdaq Composite Index ETF

0.01%

First Trust Multi-Manager Small Cap Opportunities ETF

Innovator IBD Breakout Opportunities ETF

Simplify Health Care ETF

占比2.86%

Harbor Health Care ETF

占比0.7%

Fidelity Nasdaq Composite Index ETF

占比0.01%

First Trust Multi-Manager Small Cap Opportunities ETF

占比0%

Innovator IBD Breakout Opportunities ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Abivax SA的前五大股东是谁？



Abivax SA 的前五大股东如下：
TCG Crossover Management, LLC持有股份：6.06M，占总股份比例：8.23%。
Cormorant Asset Management, LP持有股份：2.13M，占总股份比例：2.90%。
Caligan Partners, LP持有股份：1.67M，占总股份比例：2.28%。
Fidelity Management & Research Company LLC持有股份：1.01M，占总股份比例：1.38%。
Adar1 Capital Management LLC持有股份：3.07M，占总股份比例：4.17%。